Today: 20 October 2025
Subscribe
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones
 ·  ·  ·  · 

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

by
16 October 2025
  • Stock action: Femasys (NASDAQ: FEMY) jumped roughly 46% on Oct. 16, 2025, trading around $0.80 by mid-day [1] [2]. (Previous close: $0.55). This spike followed news of the company’s upcoming fertility trade-show exhibition and broader industry catalysts.
  • Key event: Femasys will exhibit at ASRM 2025 (Oct 25–29) in San Antonio, showcasing its new FemaSeed® Intratubal Insemination fertility treatment [3]. CEO Kathy Lee-Sepsick said, “We are excited to return to ASRM to share our next-generation… FemaSeed® Intratubal Insemination,” underlining the company’s focus on reproductive therapies [4].
  • Regulatory wins – FemBloc®: Femasys’ non-surgical birth control device FemBloc won key approvals in 2025. It received a CE Mark in Europe (June 2025), MHRA approval in the UK (Aug 2025) [5], and MEDSAFE approval in New Zealand (Sept 2025) [6]. These endorsements make FemBloc the first in-office, non-surgical permanent birth control available in those regions.
  • First sales & partnerships: Following EU approval, Femasys sold its first European order (~$400,000) of FemBloc to Spanish partners in mid-2025 [7]. In late Sept. the company announced a partnership with Kebomed to distribute FemBloc in France and Benelux [8], further opening the largest European markets. Globally, new fertility product partnerships were also struck: in Sept. Femasys teamed with Medical Electronic Systems (MES) to launch a FemSperm™ Analysis Kit – completing its suite of in-office sperm-prep tools for FemaSeed treatment [9]. (In August it debuted the FemSperm Setup Kit and Prep Kit for gynecologists.)
  • Other developments: Earlier this year Femasys announced Australian/New Zealand approvals for its FemaSeed infertility product and FemVue diagnostic [10], and a U.S. clinic partnership (Carolinas Fertility Institute) to roll out FemaSeed at eight locations [11]. In August it priced an $8.0 million stock financing to fund commercialization [12] (closing soon after) and reported Q2 2025 revenue of $0.409M (+85% YoY) with a smaller-than-expected net loss ($0.16/share vs. –$0.18 est.) [13].

Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination [14] [15]. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgery [16] [17].

This week’s ASRM announcement – coinciding with broader fertility news – helped lift FEMY. Also on Oct. 16, national media reported an expected US policy to expand IVF access, which analysts say has indirectly boosted Femasys’ profile. By midday on Oct. 16, FEMY was up about 46% at roughly $0.80 [18] [19] (well above its 52-week low ~$0.31 [20]). (Intraday, GuruFocus.com noted a 30% jump to $0.72 amid the IVF news, reflecting high volatility.)

Financials: Femasys is still unprofitable with a small market cap (~$30M) and past-year losses. In Q2 2025 it reported $0.41M sales (vs. $0.22M year-ago) and a net loss of $4.59M (−$0.16/share), about flat with 2024 [21]. Cash on hand was only $3.2M at Q2-end, though the recent $8M financing (Aug) will extend its runway [22]. The company expects this funding to “ramp commercialization of our FemaSeed® and FemBloc® offerings” [23].

Analyst views: Wall Street opinions are mixed. Online consensus remains bullish: for example, StockAnalysis.com shows a “Strong Buy” consensus and an average 12-month target of $7.33 (an 800%+ upside from current levels) [24]. TipRanks similarly cites an average target of about $3.83 (≈550% upside) [25]. By contrast, Weiss Ratings in early Oct. reiterated a “Sell (E+)” grade on FEMY [26]. MarketBeat notes that 3 analysts rate Femasys a Buy and 1 a Sell, giving an overall “Moderate Buy” consensus [27]. HC Wainwright (a regular coverage firm) last week trimmed its target to $8.00 (from $12) but kept a Buy rating [28].

In summary, Femasys is trading on recent product and regulatory progress. The stock’s Oct. 16 rally reflects excitement over its fertility-technology milestones (IVF-related news and ASRM expo) [29] [30]. However, analysts caution that the company still faces financial challenges (high losses, funding needs) [31]. Looking ahead, key watchpoints include further FDA updates (the pivotal “FINALE” trial for FemBloc is enrollingpatients [32] [33]), upcoming sales of FemBloc in Europe, and Femasys’ Q3 results. For now, price targets range widely. As one analyst summary put it, investors are weighing Femasys’ “next-generation infertility innovation” against its cash burn and market risks [34] [35].

Sources: Femasys press releases and SEC filings [36] [37]; Market data from Investing.com and MarketBeat [38] [39]; analyst reports (MarketBeat, StockAnalysis, TipRanks) [40] [41] [42]; industry news outlets.

References

1. www.marketbeat.com, 2. www.investing.com, 3. www.globenewswire.com, 4. www.globenewswire.com, 5. ir.femasys.com, 6. ir.femasys.com, 7. ir.femasys.com, 8. ir.femasys.com, 9. www.stocktitan.net, 10. ir.femasys.com, 11. ir.femasys.com, 12. www.stocktitan.net, 13. ir.femasys.com, 14. www.globenewswire.com, 15. www.stocktitan.net, 16. ir.femasys.com, 17. ir.femasys.com, 18. www.marketbeat.com, 19. www.investing.com, 20. www.investing.com, 21. ir.femasys.com, 22. www.stocktitan.net, 23. www.stocktitan.net, 24. stockanalysis.com, 25. www.tipranks.com, 26. www.americanbankingnews.com, 27. www.americanbankingnews.com, 28. www.americanbankingnews.com, 29. www.globenewswire.com, 30. www.marketbeat.com, 31. www.gurufocus.com, 32. www.globenewswire.com, 33. ir.femasys.com, 34. www.globenewswire.com, 35. www.americanbankingnews.com, 36. ir.femasys.com, 37. ir.femasys.com, 38. www.marketbeat.com, 39. www.investing.com, 40. www.americanbankingnews.com, 41. stockanalysis.com, 42. www.tipranks.com

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

  1. Texas Instruments (TXN) Stock Price Today Soars Amid Dividend Hike & AI Boom: Rally Ahead or More Pain? 🎯
  2. CrowdStrike Stock Climbs on AI Cybersecurity Momentum and Analyst Upgrades – What’s Next for CRWD?
  3. Palo Alto Networks Stock Near Record High – AI Boom, $25B Deal & Bold Forecasts Fuel Rally
  4. ServiceNow Stock Shines Amid AI Push and Bold Analyst Targets Ahead of Q3 Results

Related Articles

Beyond Meat Stock CRASH: 60% Plunge After Shocking Debt Swap Stuns Investors
Previous Story

Beyond Meat Shares Plunge as Debt Restructure Sparks Panic

Up 150% YTD: Navitas Semiconductor (NVTS) Rides the GaN Power Wave into AI’s Future
Next Story

Navitas (NVTS) Stock Hits All-Time High on NVIDIA AI Chip News – Will the Rally Continue?

Stock Market Today

  • Resonance Pattern Signals US Dollar Decline: Morgan Stanley's Goldilocks and All-Up Scenarios
    October 20, 2025, 1:24 AM EDT. Morgan Stanley's research identifies an 'extreme resonance' among the S&P 500, U.S. Dollar Index and 10-year Treasury yields as a lead indicator for the dollar over the next six months. Two signals stand out: the Goldilocks scenario (rally in stocks and declines in the dollar and yields) with an 83% success rate and a 3.3% average dollar decline - with the British pound leading; and the All-Up scenario (all three up) with a 73% success rate and a 2.7% dollar drop, led by the Australian dollar. The pattern has appeared multiple times in 2025 amid elevated volatility (extreme movements beyond 1.25 standard deviations). Analysts emphasize considering shorting the dollar on these signals.
  • Ant Group and JD.com pause Hong Kong stablecoin plans after Beijing warning
    October 20, 2025, 12:22 AM EDT. Ant Group and JD.com have paused plans to issue stablecoins in Hong Kong after Beijing signaled that private-sector currency issuance may be off-limits for now. The two tech giants had eyed HK's pilot for fiat-backed tokens, with Ant seeking a license to issue stablecoins once the regime was in place and JD.com eyeing an offshore yuan-backed token. Regulators led by the PBoC and the CAC instructed them to halt, signaling that the state should retain money-issuing authority. HK's Stablecoin Bill and the HKMA framework had boosted the frontier for token issuers, but officials appear to shift from enthusiasm to restraint as authorities tighten oversight and preserve currency sovereignty.
  • CRH (NYSE:CRH) Undervalued Amid Momentum: Fair Value Near $129.86
    October 19, 2025, 11:54 PM EDT. CRH has posted strong momentum, with a roughly 27% 1-year total return and a 25% 90-day surge, signaling renewed investor optimism about its growth trajectory. The current narrative places a fair value of about $129.86 versus a last close near $117.46, suggesting the stock remains undervalued by market standards, though the debate over catalysts persists. Key growth drivers include acceleration in sustainable construction and decarbonization, highlighted by the Eco Material Technologies acquisition, which could lift top-line growth and margins as the market shifts toward eco-friendly materials. Risks to watch include political shifts impacting infrastructure funding and potential missteps in large acquisitions that could temper the optimistic outlook. Investors may also consider exploring related green construction opportunities and valuation sensitivities.
  • Australian market ticks higher mid-session; ASX 200 clears 9,000 as miners retreat and energy/tech lift
    October 19, 2025, 11:50 PM EDT. Australian shares hover in modest gains at mid-session, with the S&P/ASX 200 trading above 9,000 for the first time in weeks. The index sits around 9,008.70, while the All Ordinaries nudges to about 9,304. Gains in energy and financials/tech offset declines in gold/mining names. Major miners such as Rio Tinto, Fortescue, and BHP trade lower, while Mineral Resources slides. Oil stocks like Origin Energy, Santos, Beach Energy, and Woodside advance, with Block (Afterpay), Xero, and Zip rising, though Appen slips and WiseTech Global holds steady. Gold miners drift lower, with Evolution Mining down ~5% and Newmont down ~5.5%. Banks edge higher; Bapcor plunges ~18%, and Deep Yellow drops ~17% after CEO exit. The Australian dollar sits near $0.651.
  • Walmart Stock Breakout Signals Higher Prices Ahead (NYSE: WMT)
    October 19, 2025, 11:48 PM EDT. In a move traders watch for as a bullish signal, Walmart's shares have broken out of a key consolidation pattern, suggesting the potential for higher prices ahead. If the breakout holds with convincing volume, the stock could test near-term resistance levels and set the stage for a sustained uptrend. Investors should monitor retracements for entry opportunities, ensure risk controls, and differentiate between a genuine breakout and a false move. The setup aligns with a bias toward dividend growth names and a long-term investor stance on WMT, though macro factors and retail demand trends remain key headwinds. Note the author holds a long position in WMT and the piece reflects personal views, not investment advice.
Go toTop